ArticleCHEST pulmonary2025
Combined Ultrasound-Guided Thoracentesis, Percutaneous Pleural Biopsy, and Indwelling Pleural Catheter Insertion as the First Intervention in Patients With High Likelihood of Malignant Pleural Effusion.
Article in CHEST pulmonary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative ultrasonography in surgical stabilization of rib fractures: A single-center retrospective analysis of its utility in surgical planning and post-discharge follow-up.Turk gogus kalp damar cerrahisi dergisi · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pleural effusion (MPE) indicates advanced disease and imposes a significant symptomatic burden to patients. Current guidelines recommend stepwise investigation and management. Research Question: Is it feasible and safe to combine ultrasound (US)-guided pleural biopsy and indwelling pleural catheter (IPC) insertion as the initial diagnostic and therapeutic procedure for patients with high preprocedural probability of MPE? Study Design and Methods: We retrospectively analyzed patients who underwent pleural procedures between March 1, 2021, and September 30, 2022. Sixteen patients with symptomatic unilateral pleural effusion and clinical or radiologic features suggestive of malignancy underwent combined US-guided pleural biopsy and IPC insertion as their first management step. Feasibility was determined by the number of patients requiring repeat diagnostic and therapeutic procedures, and time to diagnosis. Safety was determined by complication rates. Results: Of 258 patients who received 384 pleural procedures, 16 patients (11 male; mean age ± SD, 77 ± 9.5 years) underwent the combined procedure. All patients had high preprocedural probability of MPE as evidenced by appropriate history, a unilateral pleural effusion (93.7%), and pleural nodularity or thickening on CT chest scan or US (87.5%). Mean time to diagnostic procedure was 9.3 days. Malignancy was confirmed in 100% of cases, with mesothelioma being the most common (50%). Pleural fluid cytology was diagnostic in 3 cases (18.8%), whereas 13 US-guided pleural biopsies (81.3%) were diagnostic. Nine patients (56.25%) had their IPC removed because of autopleurodesis or treatment response, with a mean removal time of 55.8 days. At 12 months, 5 patients (31.25%) had a documented complication, with pain and catheter blockage being the most common. One patient (6.25%) developed pleural infection. Over one-half (56.2%) received antineoplastic treatment with their IPC in situ. No patient required a repeat pleural procedure on follow-up. Interpretation: A combined approach of closed, percutaneous US-guided pleural biopsy and IPC insertion as initial pleural intervention was shown to be feasible in patients with high preprocedural probability for MPE with no unexpected safety signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.